University of Liverpool | 2018 | £2.17m boost for pancreatic cancer research
New research in progress at the University of Liverpool, has been awarded over £2 million by Cancer Research UK, to identify differences in blood samples from people with newly diagnosed diabetes, to people who will develop pancreatic cancer and those who will not. Approximately 50 per cent of all people with pancreatic cancer develop diabetes before their diagnosis. At the moment researchers lack a reliable way to distinguish pancreatic cancer-linked diabetes from normal type-2 diabetes, also known as diabetes mellitus.
Now scientists at Liverpool will look for biomarkers (molecules in the blood samples) that could help them to identify people with a diabetes diagnosis who could benefit from further tests. The samples from participants will be stored in a biobank so they can be used in future studies to further research in this area (Source: University of Liverpool).
All.Can UK | December 2018| First findings of All.Can patient survey revealed at UK Parliament event
More than a third (36 per cent) of cancer patients reported the greatest inefficiency as being their diagnosis finds the All. Can patient survey sought patients’ and carers’ perspectives on inefficiencies in cancer care. 40 per cent of people who participated in the survey had been initially diagnosed with something else. A similar proportion (34 per cent) also responded to say that they had a surplus of medication left over following treatment.
All.Can worked with Quality Health to develop the patient survey. Quality Health was responsible for all aspects of survey administration and data analysis, with input from All.Can national initiatives and the international research and evidence working group.
The UK piloted the All.Can patient survey ahead of roll-out in other countries throughout 2018. The survey closed in the UK in August, but continued running until 30 November in Australia, Belgium, Canada, France, Italy, Poland, Spain and Sweden. Data from an international version is also being analysed (Source: all-can.org).
University of Edinburgh | November 2018| Bowel cancer waiting times figures revealed
Bowel cancer is the fourth most common cancer type, now researchers from the University of Edinburgh have shown that it takes 10% of patients in England and Wales more than a year from recognising the symptoms to receiving treatment for their bowel cancer. They found that 10% of people with bowel cancer in Scotland waited more than 8 months to start treatment.
This international study included anonymised medical data from 3000 patients and their doctors in Australia, and Canada alongside the UK. Among their findings people in Wales took the longest to contact their GP once they had a health concern. Patients in Wales also waited the longest time (168 days) to commence treatment, which contrasts with Denmark (77 days. Researchers found that men and women in Wales took the longest to contact their doctor once they had noticed a health concern or symptom (Source: University of Edinburgh).
Data from a newly established UK skin cancer database, the largest database of its kind in the world, has revealed that there are over 45,000 cutaneous squamous cell carcinomas (cSCC) every year in England, 350 per cent more than previous estimates suggested | JAMA Dermatology | via ScienceDaily
Developed by experts at Queen Mary University of London and Public Health England (PHE), and funded by the British Association of Dermatologists, the database fills in gaps in the recording of skin cancer, ensuring that accurate numbers for the three most common types of skin cancer: melanoma, basal cell carcinoma (BCC), and cSCC, are available for the whole of the UK.
These data are important as they enable researchers and policy makers to evaluate the effectiveness of prevention initiatives, screening, staging (the process of grading a cancer in terms of size, depth and whether it has spread to other parts of the body), and treatments for what is a very common cancer. The study has been published in JAMA Dermatology.
The first children to receive a game-changing personalised therapy for cancer will start treatment at Great Ormond Street Hospital in London this week | via NHS England
CAR-T is a highly complex new type of immunotherapy which involves collecting and using the patients’ own immune cells to target their cancer in a process which is completed over a number of weeks.
The start of this treatment marks the beginning of a new era of personalised medicine, and forms part of the upgrade in cancer services which will be set out shortly NHS’s long term plan.
In September, NHS England struck the first full access deal in Europe on tisagenlecleucel, which can potentially cure some children with B cell acute lymphoblastic leukaemia (ALL) where other treatments have failed, enabling NICE to recommend the treatment for entry into the reformed NHS Cancer Drugs Fund last week.
The landmark deal with Novartis came less than 10 days after the treatment was granted its European marketing licence and represents one of the fastest funding approvals in the 70 year history of the NHS.
The Health Foundation | November 2018 | Unfinished Business: An assessment of the national approach to improving cancer services in England 1995–2015
A major report of the progress in cancer care during the last two decades has been released by The Health Foundation. It reports that progress has been made on reducing mortality, and improving the chances of survival and the experience of care, for people in England diagnosed with cancer.
Unfinished Business sets out recommendations to help close the gap in survival between England and other comparable countries.
These include: radical improvements in early diagnosis and detection of cancer, such as increasing investment in diagnostic equipment, building public understanding of cancer symptoms, improving resourcing of primary care, greater support for GPs to refer more patients and supporting collaboration across primary and secondary care (Source: The Health Foundation).
OnMedica | November 2018 | Hope for non-toxic treatment for child cancer
One of the most common childhood cancers- neuroblastoma – has been found by researchers investigating treatments for the condition in animals. Neuroblastoma is the leading single cause of cancer in under 5s. Currently, despite using intensive treatment regimens, children with the most aggressive forms of neuroblastoma have a less than 50% survival rate. Although researchers in Australia have studied the effects of using this treatment on mice, a combination of two drugs was found to be more effective than other treatments (via OnMedica).
The research team have recently presented their findings at the 30th EORTC-NI-AACR Symposium, an event that unites academics, scientists and pharmaceutical industry representatives from across the world to discuss the latest advances and the impact of new discoveries in molecular biology. (Full story from OnMedica)
OnMedica Hope for non-toxic treatment for child cancer